Q2 EPS Estimates for Cresco Labs Lowered by Atb Cap Markets

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Equities research analysts at Atb Cap Markets lowered their Q2 2025 earnings per share (EPS) estimates for Cresco Labs in a report released on Monday, June 2nd. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings per share of ($0.05) for the quarter, down from their previous forecast of ($0.03). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Atb Cap Markets also issued estimates for Cresco Labs' Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.17) EPS.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last issued its earnings results on Friday, May 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The business had revenue of $165.76 million during the quarter, compared to the consensus estimate of $164.37 million. Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%.

CRLBF has been the topic of several other reports. Cormark upgraded Cresco Labs from a "hold" rating to a "moderate buy" rating in a research report on Monday, March 17th. Canaccord Genuity Group cut Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy".

Cresco Labs Trading Up 1.9%

CRLBF stock traded up $0.01 during midday trading on Thursday, reaching $0.54. The company's stock had a trading volume of 718,874 shares, compared to its average volume of 655,730. The business's 50-day simple moving average is $0.69 and its 200-day simple moving average is $0.84. The stock has a market cap of $265.30 million, a PE ratio of -2.70 and a beta of 1.73. Cresco Labs has a 52 week low of $0.49 and a 52 week high of $2.05. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.